CN1060078C - Chinese herbal medicine composition for curing malignant lymphoma - Google Patents
Chinese herbal medicine composition for curing malignant lymphoma Download PDFInfo
- Publication number
- CN1060078C CN1060078C CN97108402A CN97108402A CN1060078C CN 1060078 C CN1060078 C CN 1060078C CN 97108402 A CN97108402 A CN 97108402A CN 97108402 A CN97108402 A CN 97108402A CN 1060078 C CN1060078 C CN 1060078C
- Authority
- CN
- China
- Prior art keywords
- radix
- malignant lymphoma
- olibanum
- herbal
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a Chinese herbal medicine composition mainly treating malignant lymphomas. The composition is mainly prepared from seaweed, laminaria, myrrh, olibanum, fritillaria, snakegourd fruit, angelica, dried old orange peel, dyers woad leaf and dandelion, which are increased or decreased according to patients' different symptoms on the basis of main medicine components. The composition does not have toxic and side effects, and the total effective rate can reach 61%.
Description
The present invention relates to a kind of herbal composite for the treatment of malignant lymphoma, belong to the Chinese medicine technical field.
Pernicious pouring tumor belongs to the malignant tumor that is primary in lymphoreticular tissue, is one of more refractory disease in the hematopathy, treats this class disease at present both at home and abroad, and the clinical common employing excision focus of doctor trained in Western medicine also is used the treatment way of chemotherapy, radiotherapy simultaneously.Though this treatment can make conditions of patients be eased to a certain extent, can not fundamentally avoid the infringement of poison that the complication that caused by surgical operation and change, radiotherapy itself produced, side reaction to human body.Because change, radiotherapy treatment malignant lymphoma are in kill cancer cell; the many normal healthy cells of human body have also been killed; cause new chemotherapy of patient and radiation disease; make patient's heart, liver,spleen,kidney and digestive system be subjected in various degree infringement; cause body's immunity to descend; the normal hypofunction of parts of body, the state of an illness often can not get satisfied control and treatment.Though and medical circles begin above-mentioned disease already in the dialectical exploration of executing aspect controlling of Chinese medicine in domestic, eventually for want of the science compatibility of Chinese herbal medicine is caused debating disease and can not organically combine the curative effect of failing to obtain with dialectical.
Goal of the invention of the present invention is to avoid the toxic and side effects of above-mentioned western medicine therapy to the human body generation, the herbal composite of release science treatment malignant lymphoma, and promptly at the characteristics of incidence of patient's different phase, employing is debated disease and is controlled with dialectical the executing of the dialectical method that combines.Select the therapeutic scheme of best medication with a definite target in view, to obtain comparatively ideal curative effect.
Goal of the invention of the present invention can be achieved by the following technical programs: the herbal composite of this treatment malignant lymphoma is made by Sargassum, Thallus Laminariae (Thallus Eckloniae), Myrrha, Olibanum, Bulbus Fritillariae Uninbracteatae, Fructus Trichosanthis, Radix Angelicae Sinensis, Pericarpium Citri Reticulatae, Folium Isatidis, Herba Taraxaci, ten flavor Chinese herbal medicine, and each Chinese herbal medicine of distinguishing the flavor of all accounts for 10% of gross weight.Make the patient reach dissipating phlegm and resolving masses collateral dredging, promoting flow of QI and blood antidotal therapeutic effect.Clinically at patient different diseased region and characteristics of incidence, debate disease and debate with the dialectical method that combines and control adopting on above-mentioned basic side's the basis: promptly the deficiency of both QI and blood person can add Radix Codonopsis, the Radix Astragali, Colla Corii Asini, the Radix Paeoniae Alba on square substantially basis, and the percentage ratio that respectively accounts for gross weight is: Sargassum 6.8%, Thallus Laminariae (Thallus Eckloniae) 6.8%, Myrrha 6.8%, Olibanum 6.8%, Bulbus Fritillariae Uninbracteatae 6.8%, Fructus Trichosanthis 6.8%, Radix Angelicae Sinensis 6.8%, Pericarpium Citri Reticulatae 6.8%, Folium Isatidis 6.8%, Herba Taraxaci 6.8%, Radix Codonopsis 8.2%, the Radix Astragali 10.2%, Colla Corii Asini 6.8%, the Radix Paeoniae Alba 6.8%.Heating person can add Spica Prunellae, Herba Hedyotidis Diffusae, Radix Bupleuri, Radix Scutellariae on the basis of basic side, and the percentage ratio that respectively accounts for gross weight is: Sargassum 6.8%, Thallus Laminariae (Thallus Eckloniae) 6.8%, Myrrha 6.8%, Olibanum 6.8%, Bulbus Fritillariae Uninbracteatae 6.8%, Fructus Trichosanthis 6.8%, Radix Angelicae Sinensis 6.8%, Pericarpium Citri Reticulatae 6.8%, Folium Isatidis 6.8%, Herba Taraxaci 6.8%, Spica Prunellae 8.2%, Herba Hedyotidis Diffusae 10.2%, Radix Bupleuri 6.8%, Radix Scutellariae 6.8%.Stomachache person adds the Radix Paeoniae Alba, Cortex Magnoliae Officinalis, Fructus Aurantii Immaturus on the basis of basis side, and each raw material all accounts for 7.7% of gross weight.The skin lesion person that holds concurrently can add Cortex Dictamni, Radix Sophorae Flavescentis, Flos Lonicerae, Rhizoma Smilacis Glabrae on the basis of basis side, and the percentage ratio that accounts for gross weight is: Sargassum 6.9%, Thallus Laminariae (Thallus Eckloniae) 6.9%, Myrrha 6.9%, Olibanum 6.9%, Bulbus Fritillariae Uninbracteatae 6.9%, Fructus Trichosanthis 6.9%, Radix Angelicae Sinensis 6.9%, Pericarpium Citri Reticulatae 6.9%, Folium Isatidis 6.9%, Herba Taraxaci 6.9%, Cortex Dictamni 10.3%, Radix Sophorae Flavescentis 6.9%, Flos Lonicerae 6.9%, Rhizoma Smilacis Glabrae 6.9%.Patient's lymph tumor is sent out in incidence person can add Radix Platycodonis, Rhizoma Cimicifugae on the basis of basic side, and the percentage ratio that accounts for gross weight respectively is: Sargassum 8.4%, Thallus Laminariae (Thallus Eckloniae) 8.4%, Myrrha 8.4%, Olibanum 8.4%, Bulbus Fritillariae Uninbracteatae 8.4%, Fructus Trichosanthis 8.4%, Radix Angelicae Sinensis 8.4%, Pericarpium Citri Reticulatae 8.4%, Folium Isatidis 8.4%, Herba Taraxaci 8.4%, Radix Platycodonis 8.4%, Rhizoma Cimicifugae 7.6%.Patient tumors is sent out in the person of throat can add Radix Platycodonis, Radix Scrophulariae, Rhizoma Belamcandae on the basis in basis side, and the percentage ratio that accounts for gross weight is: Sargassum 7.6%, Thallus Laminariae (Thallus Eckloniae) 7.6%, Myrrha 7.6%, Olibanum 7.6%, Bulbus Fritillariae Uninbracteatae 7.6%, Fructus Trichosanthis 7.6%, Radix Angelicae Sinensis 7.6%, Pericarpium Citri Reticulatae 7.6%, Folium Isatidis 7.6%, Herba Taraxaci 7.6%, Radix Platycodonis 7.6%, Radix Scrophulariae 9.1%, Rhizoma Belamcandae 7.6%.
The present invention compared with prior art has following good effect: not only avoided adopting the poison of western medical treatment human body to pay effect, simultaneously owing to the dissipating phlegm and resolving masses collateral dredging of the present invention with theory of Chinese medical science, the promoting flow of QI and blood detoxifcation is main, it is according to patient's clinical manifestation and treat with disease, as using Sargassum, Thallus Laminariae (Thallus Eckloniae), Fructus Trichosanthis, Bulbus Fritillariae Uninbracteatae in the compatibility of drugs with dissipating phlegm and resolving masses, with Pericarpium Citri Reticulatae with promoting the circulation of QI and reducing phlegm, with Olibanum, Myrrha, Radix Angelicae Sinensis with blood circulation promoting and blood stasis dispelling, with Folium Isatidis, Herba Taraxaci with heat-clearing and toxic substances removing, all medicines share, patient's persistent ailment is alleviated, and the life-span prolongs.Be better than simple the application and set upright the nuclear that disappears, the expectorant blood stasis dispelling, heat-clearing and toxic substances removing etc. are only limited to according to the clinical manifestation in a certain stage of disease takes single Therapeutic Method.After the clinical use, truly have unexpected curative effect, 31 routine patients of following table statistics are in hospital above county level and make a definite diagnosis the malignant lymphoma person of seeking medical advice that comes, wherein male 15 examples, women 16 examples; Divide the apoplexy due to endogenous wind Hokdkin disease 29 examples, sick 2 examples of Fei Hejiejinshi.Site of pathological change: 15 examples under the jaw, 7 examples on the clavicle, nasopharynx part 3 examples, multiple person's 4 examples on the clavicle, before and after the oxter, ear, throat's 1 example, gastric lymphosarcoma 1 example, the course of treatment 8～10 the course of treatment person's 23 examples, 10 courses of treatment above person's 8 examples.Efficacy analysis:
| Age group | Sex | Number | Alleviate fully | Part is alleviated | Invalid |
| Under-18s | The man | 4 | 1 | 1 | 2 |
| The woman | 2 | 1 | 1 | ||
| 19-49 year | The man | 6 | 1 | 4 | 1 |
| The woman | 12 | 1 | 7 | 4 | |
| More than 50 years old | The man | 5 | 1 | 1 | 3 |
| The woman | 2 | 1 | 1 | ||
| Subtotal | 31 | 5 | 14 | 12 | |
Criterion of therapeutical effect:
Alleviate fully: the lymph node of enlargement disappears, and sick inspection lymph structure is normal, and clinical symptom disappearance is followed up a case by regular visits to not recurrence more than 5 years.
Part is alleviated: enlarged lymph node obviously dwindles, and sick inspection lymph node structure part is unusual, and clinical symptoms is improved.
Invalid: treatment back enlarged lymph node and clinical symptoms do not have obvious change.
Advance to introduce embodiments of the invention below:, to patient's clinical observation, think that " disease the is long-pending " diseases such as " Concha Solen gouldii warts " in this disease and the traditional Chinese medical science treatise has similarity by for many years about the origin cause of formation problem of malignant lymphoma.According to saying of ancients " no expectorant is nucleation not ", cause the main cause of malignant lymphoma disease mostly to be stagnation of liver-QI with the passing of time, stagnated QI transforming into fire, fire-toxin fluid transformed into phlegm by fire, the expectorant poison stasis of blood is fought to tie and is formed, or because of the temper element loses, fortuneization mistake department, water is wet not to be transported, cohesion is expectorant, accumulation of phlegm with the passing of time, it is primary disease that the expectorant poison stasis of blood is tied in the lining, this is to produce pathology thought of the present invention.And expectorant poison stop place difference, clinical manifestation is also different.Be listed below embodiment:
Example 1: the basic compatibility of treatment malignant lymphoma herbal composite: Sargassum 10g, Thallus Laminariae (Thallus Eckloniae) 10g, Myrrha 10g, Olibanum 10g, Bulbus Fritillariae Uninbracteatae 10g, Fructus Trichosanthis 10g, Radix Angelicae Sinensis 10g, Pericarpium Citri Reticulatae 10g, Folium Isatidis 10g, Herba Taraxaci 10g;
Example 2: the malignant lymphoma patient for deficiency of both QI and blood can add Radix Codonopsis 12g, Radix Astragali 15g, Colla Corii Asini 10g, Radix Paeoniae Alba 10g on the basis of example 1 basic compatibility;
Example 3: can on the basis of example 1 basic compatibility, add Spica Prunellae 12g, Herba Hedyotidis Diffusae 15g, Radix Bupleuri 10g, Radix Scutellariae 10g for the fever type patient;
Example 4: can on the basis of example 1 basic compatibility, add Radix Paeoniae Alba 10g, Cortex Magnoliae Officinalis 10g, Fructus Aurantii Immaturus 10g for the abdominal pain type patient;
Example 5: the patient for the skin lesion of holding concurrently can add Cortex Dictamni 15g, Radix Sophorae Flavescentis 10g, Flos Lonicerae 10g, Rhizoma Smilacis Glabrae 10g on the basis of example 1 basic compatibility;
Example 6: send out in incidence person for malignant lymphoma and can on the basis of example 1 basic compatibility, add Radix Platycodonis 10g, Rhizoma Cimicifugae 9g;
Example 7: be positioned at the person of throat for the malignant lymphoma focus and can on the basis of example 1 basic compatibility, add Radix Platycodonis 10g, Radix Scrophulariae 12g, Rhizoma Belamcandae 10g.
Above-mentioned each example, every day potion, 10 doses was 1 course of treatment.
The present invention tests through animal toxicity, has no side effect and other untoward reaction.
Claims (7)
1. herbal composite for the treatment of malignant lymphoma, it is characterized in that said composition made by Sargassum, Thallus Laminariae (Thallus Eckloniae), Myrrha, Olibanum, Bulbus Fritillariae Uninbracteatae, Fructus Trichosanthis, Radix Angelicae Sinensis, Pericarpium Citri Reticulatae, Folium Isatidis, Herba Taraxaci ten flavor Chinese herbal medicine, the content of each Chinese herbal medicine of distinguishing the flavor of all accounts for 10% of gross weight.
2. a herbal composite for the treatment of malignant lymphoma is characterized in that the percentage ratio of making the herbal raw material of said composition and accounting for gross weight is: Sargassum 6.8%, Thallus Laminariae (Thallus Eckloniae) 6.8%, Myrrha 6.8%, Olibanum 6.8%, Bulbus Fritillariae Uninbracteatae 6.8%, Fructus Trichosanthis 6.8%, Radix Angelicae Sinensis 6.8%, Pericarpium Citri Reticulatae 68%, Folium Isatidis 6.8%, Herba Taraxaci 6.8%, Radix Codonopsis 8.2%, the Radix Astragali 10.2%, Colla Corii Asini 6.8%, the Radix Paeoniae Alba 6.8%.
3. a herbal composite for the treatment of malignant lymphoma is characterized in that the percentage ratio of making the herbal raw material of said composition and accounting for gross weight is: Sargassum 6.8%, Thallus Laminariae (Thallus Eckloniae) 6.8%, Myrrha 6.8%, Olibanum 6.8%, Bulbus Fritillariae Uninbracteatae 6.8%, Fructus Trichosanthis 6.8%, Radix Angelicae Sinensis 6.8%, Pericarpium Citri Reticulatae 68%, Folium Isatidis 6.8%, Herba Taraxaci 6.8%, Spica Prunellae 8.2%, Herba Hedyotidis Diffusae 10.2%, Radix Bupleuri 6.8%, Radix Scutellariae 6.8%.
4. herbal composite for the treatment of malignant lymphoma, it is characterized in that the herbal raw material of making said composition is: Sargassum, Thallus Laminariae (Thallus Eckloniae), Myrrha, Olibanum, Bulbus Fritillariae Uninbracteatae, Fructus Trichosanthis, Radix Angelicae Sinensis, Pericarpium Citri Reticulatae, Folium Isatidis, Herba Taraxaci, the Radix Paeoniae Alba, Cortex Magnoliae Officinalis, Fructus Aurantii Immaturus, the content of each Chinese herbal medicine of distinguishing the flavor of all accounts for 7.7% of gross weight.
5. a herbal composite for the treatment of malignant lymphoma is characterized in that the percentage ratio of making the herbal raw material of said composition and accounting for gross weight is: Sargassum 6.9%, Thallus Laminariae (Thallus Eckloniae) 6.9%, Myrrha 6.9%, Olibanum 6.9%, Bulbus Fritillariae Uninbracteatae 6.9%, Fructus Trichosanthis 6.9%, Radix Angelicae Sinensis 6.9%, Pericarpium Citri Reticulatae 6.9%, Folium Isatidis 6.9%, Herba Taraxaci 6.9%, Cortex Dictamni 10.3%, Radix Sophorae Flavescentis 6.9%, Flos Lonicerae 6.9%, Rhizoma Smilacis Glabrae 6.9%.
6. a herbal composite for the treatment of malignant lymphoma is characterized in that the percentage ratio of making the herbal raw material of said composition and accounting for gross weight is: Sargassum 8.4%, Thallus Laminariae (Thallus Eckloniae) 8.4%, Myrrha 8.4%, Olibanum 8.4%, Bulbus Fritillariae Uninbracteatae 8.4%, Fructus Trichosanthis 8.4%, Radix Angelicae Sinensis 8.4%, Pericarpium Citri Reticulatae 8.4%, Folium Isatidis 8.4%, Herba Taraxaci 8.4%, Radix Platycodonis 8.4%, Rhizoma Cimicifugae 7.6%.
7. a herbal composite for the treatment of malignant lymphoma is characterized in that the percentage ratio of making the herbal raw material of said composition and accounting for gross weight is: Sargassum 7.6%, Thallus Laminariae (Thallus Eckloniae) 7.6%, Myrrha 7.6%, Olibanum 7.6%, Bulbus Fritillariae Uninbracteatae 7.6%, Fructus Trichosanthis 7.6%, Radix Angelicae Sinensis 7.6%, Pericarpium Citri Reticulatae 7.6%, Folium Isatidis 7.6%, Herba Taraxaci 7.6%, Radix Platycodonis 7.6%, Radix Scrophulariae 9.1%, Rhizoma Belamcandae 7.6%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97108402A CN1060078C (en) | 1997-01-13 | 1997-01-13 | Chinese herbal medicine composition for curing malignant lymphoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97108402A CN1060078C (en) | 1997-01-13 | 1997-01-13 | Chinese herbal medicine composition for curing malignant lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1188011A CN1188011A (en) | 1998-07-22 |
| CN1060078C true CN1060078C (en) | 2001-01-03 |
Family
ID=5170394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97108402A Expired - Fee Related CN1060078C (en) | 1997-01-13 | 1997-01-13 | Chinese herbal medicine composition for curing malignant lymphoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1060078C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102847025A (en) * | 2012-10-15 | 2013-01-02 | 原志成 | Medicine for lymph drainage and preparation method thereof |
| CN103169807A (en) * | 2013-04-11 | 2013-06-26 | 太仓市胜舟生物技术有限公司 | Application of Chinese and western combined medicine in pharmacy |
| CN103505698A (en) * | 2013-07-30 | 2014-01-15 | 卢金贵仙 | Traditional Chinese medicine composition for treating malignant lymphoma |
| CN104940823B (en) * | 2015-06-26 | 2018-08-21 | 上海交通大学医学院附属瑞金医院 | A kind of a kind of reed mentioned in ancient books Huang mixture for treating B cell lymphoma and its application |
| CN105056111A (en) * | 2015-07-30 | 2015-11-18 | 陈维松 | Traditional Chinese medicinal pill for treating hodgkin lymphoma |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1057399A (en) * | 1990-06-18 | 1992-01-01 | 李文升 | A kind of manufacture method of Chinese medicine atomic powder for clearing lump in abdomen |
| CN1111999A (en) * | 1994-08-09 | 1995-11-22 | 马洪万 | Cancer therapy injection |
-
1997
- 1997-01-13 CN CN97108402A patent/CN1060078C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1057399A (en) * | 1990-06-18 | 1992-01-01 | 李文升 | A kind of manufacture method of Chinese medicine atomic powder for clearing lump in abdomen |
| CN1111999A (en) * | 1994-08-09 | 1995-11-22 | 马洪万 | Cancer therapy injection |
Non-Patent Citations (3)
| Title |
|---|
| 《中级医刊》23(10) 1988.10.31 尹素云，恶性淋巴瘤的中医中药治疗 * |
| 《北京中医》(5) 1985.5.31 潘敏球，加减四物消瘰汤治疗恶性淋巴瘤10例小结 * |
| 《北京中医》(5) 1985.5.31 潘敏球，加减四物消瘰汤治疗恶性淋巴瘤10例小结;《中级医刊》23(10) 1988.10.31 尹素云，恶性淋巴瘤的中医中药治疗 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1188011A (en) | 1998-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100509014C (en) | Medicament for treating mammitis | |
| CN101461921B (en) | Medicinal composition for treating gynecopathy | |
| CN101934025B (en) | Traditional Chinese medicine for clearing away heat and toxic material | |
| CN103041317B (en) | A kind of Chinese medicine composition for the treatment of tumor and preparation method thereof | |
| CN104523865B (en) | Medicine for treating breast diseases | |
| CN101797366A (en) | Drug composition for treating tumor | |
| CN103272096A (en) | Traditional Chinese medicine for treating dysmenorrhea | |
| CN101658657B (en) | Drug for treating chronic cholecystitis | |
| CN1088369C (en) | Moxibustion liquid --moxibustion fixing paste and its preparation method and use method | |
| CN100444888C (en) | The Chinese herbal medicinal pills for treatment of hepatitis B and liver cancer | |
| CN1060078C (en) | Chinese herbal medicine composition for curing malignant lymphoma | |
| CN102475868A (en) | Anti-rheumatism medicinal liquor | |
| CN101313952A (en) | Traditional Chinese herb medicine for treating cancer | |
| CN1351872A (en) | Chinese herbal medicine for curing comedo and acne | |
| CN104606639B (en) | A kind of Chinese medicine for treating acute mastitis milk obstruction | |
| CN101002848A (en) | Medicine for treating recurrent uarthritis, and its preparing method | |
| CN103977216A (en) | Traditional Chinese medicinal preparation for treating irradiated brain stem type myeloen cephalospinal disease | |
| CN103393909A (en) | Chinese medicinal preparation for treating biliary calculus with cholecystitis | |
| CN107596295A (en) | It is a kind of to be used to treat Chinese medicine preparation of lung cancer and preparation method thereof | |
| CN103505670A (en) | Traditional Chinese medicine composition for treating primary bronchus lung cancer | |
| CN103028059B (en) | Traditional Chinese medicine composition for treating cholangiocarcinoma | |
| CN101912566B (en) | Traditional Chinese medicine for treating palpitation | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN106581612A (en) | Traditional Chinese medicine recipe for treating pulmonary heart disease | |
| CN105796989A (en) | Traditional Chinese medicine composition for treating leukemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1053566 Country of ref document: HK |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |